

Sample Received: April 21, 2026

COA Issued: April 27, 2026

PRODUCT INFORMATION

|                           |                             |                                          |                         |                     |
|---------------------------|-----------------------------|------------------------------------------|-------------------------|---------------------|
| Vendor:<br>Bwell Peptides | Sample Name:<br>GLP-3R 30mg | Sample Type:<br>White lyophilized powder | Lot Number:<br>R302604A | MW:<br>4731.3 g/mol |
|---------------------------|-----------------------------|------------------------------------------|-------------------------|---------------------|


ANALYTICAL METHODS

Identity: Confirmed via MALDI-MS  
Purity: RP-HPLC (214 nm)  
Content: HPLC quantitation

TEST RESULTS

| Specification    | Result      | Method            | Status     |
|------------------|-------------|-------------------|------------|
| Identity: GLP-3R | GLP-3R      | MALDI-MS          | ✓ Conforms |
| Content          | 30.46 mg    | HPLC Quantitation | ✓ Conforms |
| Overall Purity   | 99.8%       | RP-HPLC (214 nm)  | ✓ Conforms |
| Endotoxin        | <0.05 EU/mL | <USP85>           | ✓ Conforms |

HPLC Chromatogram (Retention Time: 10.317 min)



Certification: This COA confirms that the tested material meets or exceeds Bioviridian’s analytical quality specifications for peptide research use.

Shane Straight

Shane Straight, M.S.  
Principal Chemist, Bioviridian Inc.